HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Balance Sheet
EBR:HYL - Euronext Brussels - BE0974363955 - Common Stock - Currency: EUR
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 30.20M | 43.46M | 50.01M | 64.40M | 205.00K | |||
| Marketable Securities | 499.00K | 10.47M | 528.00K | 7.00K | 0.00 | |||
| Receivables | 3.81M | 4.13M | 2.32M | 253.00K | 333.00K | |||
| Other Current Assets | 594.00K | 1.75M | 1.10M | 1.95M | 3.20M | |||
| Total Current Assets | 35.31M | 49.80M | 53.96M | 66.61M | 3.74M | |||
| Non-Current Assets | ||||||||
| PPE Net | 2.15M | 1.06M | 295.00K | 176.00K | 98.00K | |||
| Investments And Advances | 4.80M | 4.95M | 4.53M | 12.00K | 9.00K | |||
| Intangibles | 3.83M | 3.61M | 2.94M | 2.38M | 2.14M | |||
| Other Non-Current Assets | 1.59M | 1.31M | 1.71M | N/A | -1.00K | |||
| Total Non-Current Assets | 12.37M | 10.93M | 9.48M | 2.57M | 2.24M | |||
| TOTAL ASSETS | 47.68M | 60.73M | 63.44M | 69.18M | 5.98M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 241.00K | 138.00K | 65.00K | 46.00K | 44.00K | |||
| Accounts Payable | 3.32M | 2.42M | 2.75M | 1.63M | 2.92M | |||
| Other Current Liabilities | 3.20M | 3.21M | 12.16M | 457.00K | 13.19M | |||
| Total Current Liabilities | 6.76M | 5.77M | 14.98M | 2.13M | 16.15M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.51M | 747.00K | 109.00K | 106.00K | 22.00K | |||
| Other Non-Current Liabilities | 343.00K | 300.00K | 301.00K | 7.88M | N/A | |||
| Total Non-Current Liabilities | 1.85M | 1.05M | 410.00K | 7.99M | 22.00K | |||
| TOTAL LIABILITIES | 8.61M | 6.82M | 15.39M | 10.12M | 16.17M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -80.28M | -64.91M | -55.77M | -44.76M | -34.26M | |||
| Additional Paid In Capital | 121.51M | 121.51M | 103.69M | 103.69M | 23.98M | |||
| Minority Interest | N/A | N/A | N/A | N/A | 0.00 | |||
| Common Shares | 140.00K | 140.00K | 129.00K | 129.00K | 89.00K | |||
| Other Shareholders' Equity | -2.30M | -2.84M | -1.00K | N/A | N/A | |||
| Shares Outstanding | 28.00M | 28.00M | 25.83M | 25.59M | 17.80M | |||
| Tangible Book Value per Share | 1.26 | 1.80 | 1.75 | 2.21 | -0.69 | |||
| Total Shareholders' Equity | 39.07M | 53.91M | 48.06M | 59.06M | -10.19M | |||
| TOTAL LIABILITIES AND EQUITY | 47.68M | 60.73M | 63.44M | 69.18M | 5.98M | |||
| Statistics | ||||||||
| Debt/Equity | 0.04 | 0.01 | 0.00 | 0.00 | -0.00 | |||
| Current Ratio | 5.22 | 8.63 | 3.60 | 31.24 | 0.23 | |||
| Return On Assets (ROA) | -32.26% | -19.61% | -18.25% | -10.33% | -96.41% | |||
| Return On Equity (ROE) | -39.37% | -22.09% | -24.09% | -12.10% | N/A | |||
All data in EUR , ROIC based on taxRate of 0.25